Contact this trialFirst, we need to learn more about you.
Kinase Inhibitor
Aurora A Kinase Inhibitor + Osimertinib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial tests a combination of two drugs, LY3295668 and osimertinib, in patients with advanced lung cancer that has a specific mutation and has spread. The drugs work by blocking enzymes and mutations that help cancer cells grow. Osimertinib is a third-generation treatment approved for advanced non-small cell lung cancer with specific mutations.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service